Article Text

Download PDFPDF

Increasing contraception use among women receiving teratogenic medications in a rheumatology clinic
  1. Rebecca E Sadun1,
  2. Melissa A Wells2,
  3. Stephen J Balevic1,
  4. Victoria Lackey3,
  5. Erica J Aldridge4,
  6. Nicholas Holdgagte5,
  7. Samya Mohammad6,
  8. Lisa G Criscione-Schreiber1,
  9. Megan E B Clowse1,
  10. Mamata Yanamadala7
  1. 1 Division of Rheumatology, Department of Medicine, Duke Health, Durham, North Carolina, USA
  2. 2 Colorado Center for Arthritis and Osteoporosis, Boulder, Colorado, USA
  3. 3 Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, USA
  4. 4 Baptist Medical Group Rheumatology, Pensacola, Florida, USA
  5. 5 Lowcountry Rheumatology, Charleston, South Carolina, USA
  6. 6 EmergeOrtho, Durham, North Carolina, USA
  7. 7 Division of Geriatrics, Department of Medicine, Duke Health, Durham, North Carolina, USA
  1. Correspondence to Dr Rebecca E Sadun; rebecca.sadun{at}duke.edu

Abstract

Teratogenic medications are often prescribed to women of childbearing age with autoimmune diseases. Literature suggests that appropriate use of contraception among these women is low, potentially resulting in high-risk unintended pregnancies. Preliminary review in our clinic showed suboptimal documentation of women’s contraceptive use. We therefore designed a quality improvement initiative to target three process measures: documentation of contraception usage and type, contraception counselling and provider action after counselling. We reviewed charts of rheumatology clinic female patients aged 18–45 over the course of 10 months; for those who were on teratogenic medications (methotrexate, leflunomide, mycophenolate and cyclophosphamide), we looked for evidence of documentation of contraception use. We executed multiple plan-do-study-act (PDSA) cycles to develop and evaluate interventions, which centred on interprofessional provider education, modification of electronic medical record (EMR) templates, periodic provider reminders, patient screening questionnaires and frequent feedback to providers on performance. Among eligible patients (n=181), the baseline rate of documentation of contraception type was 46%, the rate of counselling was 30% and interventions after counselling occurred in 33% of cases. Averaged intervention data demonstrated increased provider performance in all three domains: documentation of contraception type increased to 64%, counselling to 45% and provider action to 46%. Of the patients with documented contraceptives, 50% used highly effective, 27% used effective and 23% used ineffective contraception methods. During this project, one unintentional pregnancy occurred in a patient on methotrexate not on contraception. Our interventions improved three measures related to contraception counselling and documentation, but there remains a need for ongoing quality improvement efforts in our clinic. This high-risk population requires increased provider engagement to improve contraception compliance, coupled with system-wide EMR changes to increase sustainability.

  • continuous quality improvement
  • women’s health
  • pdsa
  • implementation science
  • ambulatory care

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors RES, MAW, SJB and MY contributed to manuscript writing. All authors contributed to study planning, data collection and manuscript editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.